Piramal Pharma Agrees to Acquire Hemmo Pharmaceuticals

CDMO Piramal Pharma Solutions (PPS), based in Mumbai, India, agreed to acquire a 100% stake in Hemmo Pharmaceuticals in a deal that will add peptide API development and manufacturing capabilities to PPS’ operations.

Hemmo, which is one of the few pure-play synthetic peptide API manufacturers in the global marketplace, according to PPS, is one of India’s largest manufacturers of synthetic peptides with a history of more than thirty-eight years in supplying peptide products and custom peptide synthesis. Hemmo reportedly has R&D capabilities and a world-class GMP manufacturing facility that has been inspected and deemed compliant by the U.S., EU, and Asian regulatory agencies. The company has strong expertise in both solution phase and solid phase synthesis of peptides, notes Nandini Piramal, chairperson, PPS.

“Hemmo has demonstrated excellence and a great quality track record with a differentiated and hard to replicate capability,” adds Piramal.

The acquisition is expected to add more than two-hundred and fifty employees to PPS, including several PhD scientists and a quality team of more than sixty.

Products You May Like

Articles You May Like

Metabolite Compound Delays Progression of Duchenne Muscular Dystrophy in Mice
Former home of TV’s Natalie Morales sells in Hoboken for $3M
Why that prefeasibility study needs a big warning label
Entrepreneur Franchise of the Day: Great Clips
Christina Haack lists house with estranged husband Ant Anstead for $6M

Leave a Reply

Your email address will not be published. Required fields are marked *